期刊文献+

^(18)F-FDGPET/CT在寻找不明原发灶肿瘤患者原发灶中的价值 被引量:3

Value of Detecting Primary Focus in Carcinoma of Unknown Primary Using ^(18)F-FDG PET/CT
下载PDF
导出
摘要 目的探讨18F-FDGPET/CT在诊断不明原发灶肿瘤(CUP)患者原发灶中的价值。资料与方法36例CUP患者行PET/CT检查拟寻找原发灶,根据转移灶部位分为淋巴结转移组(8例)、肝转移组(9例)、骨转移组(12例)及恶性胸腹水组(7例),比较18F-FDGPET/CT诊断淋巴结转移组与非淋巴结转移组CUP患者原发灶的灵敏度。结果 18F-FDGPET/CT寻找CUP原发灶的灵敏度为63.9%(23/36),PET/CT诊断淋巴结转移组、肝转移组、骨转移组及恶性胸腹水组患者原发灶的灵敏度分别为87.5%(7/8)、55.6%(5/9)、58.3%(7/12)、57.1%(4/7)。18F-FDGPET/CT对淋巴结转移组原发灶的确诊率[87.5%(7/8)]显著高于非淋巴结转移组[57.1%(16/28)],差异有统计学意义(P<0.05)。结论 18F-FDGPET/CT诊断CUP患者原发灶灵敏度较高,尤其适用于发生淋巴结转移的CUP患者。 Purpose To explore the value of 18 F-FDG PET/CT in the diagnosis of primary focus for patients with carcinoma of unknown primary (CUP).Materials and Methods Thirty-six patients with CUP underwent PET/CT to detect the primary focus,and further divided into lymph node metastasis group (n=8),liver metastasis group (n =9),bone metastasis group (n=12),malignant hydrothorax and ascites group (n=7) according to sites of metastasis.The sensitivity of diagnosing primary focus in patients with CUP between lymph node metastasis group and nonlymph node metastasis group using PET/CT was analyzed.Results The sensitivity of 18 F-FDG PET/CT in detecting primary focus for patients with CUP was 63.9% (23/36),the sensitivities in lymph node metastasis group,liver metastasis group,bone metastasis group,malignant hydrothorax and ascites group were 87.5% (7/8),55.6% (5/9),58.3% (7/12),57.1% (4/7),respectively.The diagnostic rate in lymph node metastasis group [87.5% (7/8)] was statistically higher than that of non-lymph node metastasis group [57.1% (16/28)] (P〈0.05).Conclusion 18 F-FDG PET/CT is sensitive to diagnose the primary focus for patients with CUP,especially for patients with lymph node metastasis.
出处 《中国医学影像学杂志》 CSCD 北大核心 2012年第6期468-470,共3页 Chinese Journal of Medical Imaging
关键词 肿瘤 未知原发灶 正电子发射断层显像术 氟脱氧葡萄糖F18 Neoplasms, unknown primary Positron-emission tomography Fluorodeoxyglucose F 18
  • 相关文献

参考文献10

  • 1Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol, 2009, 69(3): 271-278.
  • 2Roh JL, Kim JS, Lee JH, et al. Utility of combined (18) F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors. Oral Oncol, 2009, 45(3): 218-224.
  • 3Gutzeit A, Antoch G, Kiihl H, et al. Unknown primary tumors: detection with dual-modality PET/CT--initial experience. Radiology, 2005, 234(1): 227-234.
  • 4Le Chevalier T, Cvitkovic E, Caille P, et al. Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med, 1988, 148(9): 2035-2039.
  • 5Fritz A, Percy C, Jack A. International classification of diseases for oncology (ICD-O). 3rd ed. Geneva: World Health Organization, 2000:276-279.
  • 6Seve P, Sawyer M, Hanson J, et al. The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study. Cancer, 2006, 106(9): 2058-2066.
  • 7Zhang M, Jiang X, Zhang M, et al. The role of ^18F-FDG PET/CT in the evaluation of ascites of undetermined origin. J Nucl Meal, 2009, 50(4): 506-512.
  • 8郑容,吴宁,李静,张雯杰,刘瑛,赵平.^(18)F-FDG PET/CT显像在寻找转移性肿瘤原发灶中的应用[J].中国临床医学影像杂志,2008,19(3):164-167. 被引量:9
  • 9Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of ^18F-FDG PET in oncology. J Nucl Med, 2008, 49(3): 480-508.
  • 10Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol, 2009, 19(3): 731-744.

二级参考文献16

  • 1李亚军,高硕,陈秋松,李彦生,邢喜玲.^(18)F-FDGPET/CT显像探测原发肿瘤病灶的临床价值[J].中华核医学杂志,2005,25(1):37-38. 被引量:10
  • 2van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, et al. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992[J]. Eur J Cancer, 2002, 38(3): 409-413.
  • 3Abruzzese JL, Abbruzzese MC, Hess KR, et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients[J]. J Clin Oncol, 1994, 12(6): 1272-1280.
  • 4Seve P, Sawyer M, Hanson J, et al. The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study[J]. Cancer, 2006, 106(9): 2058-2065.
  • 5Seve P, Billotey C, Broussolle C, et al. The role of 2-deoxy-2- [F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site [J]. Cancer, 2007, 109 (2): 292-299,
  • 6Zhao J, Lin XT, Guan YH, et al. Detection of unknown primary tumor using whole body FDG PET [J]. Chinese-German J Clin Oncol, 2003, 2(3): 179-183.
  • 7Hany TF, Steinert HC, Goerres GW, et al. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results[J]. Radiology, 2002, 225(2): 575-581.
  • 8Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET Ⅲ", 21 July and 19 September 2000[J]. Eur J Nucl Med, 2001,28(11): 1707-1723.
  • 9Pelosi E, Pennone M, Deandreis D, et al. Role of whole body positron emission tomography/computed tomography scan with ^18F- fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site [J]. Q J Nucl Med Mol Imaging, 2006, 50(1): 15-22.
  • 10Gutzeit A, Antoch G, Kuhl H, et al. Unknown primary tumors: detection with dual-modality PET/CT--initial experience[J]. Radiology, 2005, 234(1): 227-234.

共引文献8

同被引文献27

  • 1吴建波,王建斌,李勇,等.NK细胞治疗晚期恶性肿瘤转移灶的临床观察[J].中国美容医学,2012,21(z1):72-74.
  • 2宫丽华,孙晓淇,刘宝岳,等.前列腺癌骨转移灶中BMP-2、BMP-4、BMP-7的表达及临床意义[J].临床与文验病理学杂志,2012.28(8):870-873.
  • 3Valerie WR, Hisao A, Hirokazu W, et al. The IASLC lung cancer staging project. J Thoraci Oncol, 2009, 4(5): 568-577.
  • 4Cuaron J, Dunphy M, Rimner A. Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer. Front Oncol, 2012, 2(2): 208.
  • 5Ose N, Sawabata Noriyoshi, Minami M, et al. Lymph node metastasis diagnosis using positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose as a tracer and computed tomography in surgical cases of non-small cell lung cancer. Eur J Cardiothorac Surg, 2012, 42(1): 89-92.
  • 6Kligerman S, Digumarthy S. Staging of non-small cell lung cancer using integrated PET/CT. Am J Roentgenol, 2009, 193(5): 1203-1211.
  • 7Gregory DL, Hicks R J, Hogg A, et al. Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data. J Nucl Med, 2012, 53(7): 1007-1015.
  • 8Ford EC, Herman J, Yorke E, et al. 18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. J Nucl Med, 2009, 50(10): 1655-1665.
  • 9Fischer BM, Mortensen J, Hansen H, et al. Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial. Thorax, 2011, 66(4): 294-300.
  • 10Bille A, Pelosi E, Skanjeti A, et al. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. Eur J Cardiothorac Surg, 2009, 36(3): 440-445.

引证文献3

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部